Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors;Prévention, par un inhibiteur de kinases cycline-dépendantes, de l'alopécie induite par la chimiothérapie

Bulletin du Cancer

Volumn 88, Issue 4, 2001, Pages 347-350

  Meijer, L ^a   Knockaert, M ^a   Damiens, E ^a  

^a STATION BIOLOGIQUE   (France)

Author keywords

Alopecia; Chemotherapy; Cyclin dependent kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE;

ALOPECIA; CELL CYCLE; CELL DIVISION; CELL PROTECTION; HUMAN; REVIEW; TISSUE INJURY;

ALOPECIA; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASES; CYTOPROTECTION; ENZYME INHIBITORS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035024827     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Inhibiteurs chimiques des kinases dépendantes des cyclines: Recherche et applications thérapeutiques potentielles
2. Mechanisms of cyclin-dependent kinase regulation: Structures of cdks, their cyclin activators, and Cip and INK4 inhibitors
3. CDK inhibitors: Positive and negative regulators of G1-phase progression
4. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors
5. Chemical inhibitors of cyclin-dependent kinases
6. ATP-site directed inhibitors of cyclin-dependent kinases
7. Inhibitors of cyclin-dependent kinases as anticancer therapeutics
8. Cyclin-dependent kinases inhibitors as potential anticancer, anti-neurodegenerative, anti-viral and anti-parasitic agents
9. Cyclin-dependent kinase inhibitors: Novel anticancer agents
10. Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
11. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation
12. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
13. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons
14. Inhibition of cyclin-dependent kinases by purine derivatives
15. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
16. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors
17. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
18. Indirubins inhibit glycogen synthase kinase - 3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most CDK inhibitors?
19. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumor cells
20. The paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
21. Paullones are potent inhibitors of glycogen synthase kinase - 3β and cyclin-dependent kinase 5/p25
22. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent
23. Identification of novel purine and pyrimidine cycline-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
24. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases
25. Inhibiteurs chimiques des kinases cyclines-dépendantes
26. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors
27. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised ligants